A Phase II Study of CC-486 plus Standard Chemotherapy (CHOP) for Patients with Previously Untreated Peripheral T-Cell Lymphoma


Full Title

A Multi-center Phase II study of CC486-CHOP in Patients with Previously Untreated Peripheral T-cell Lymphoma


CHOP is a combination of four chemotherapy drugs traditionally used to treat peripheral T-cell lymphoma. In this study, researchers are assessing the safety and effectiveness of adding the investigational drug CC-486 (oral azacitidine) to CHOP therapy in patients with peripheral T-cell lymphoma who have not yet been treated.

CC-486 works by changing which genes are active in cancer cells, which can make cancer cells more likely to die in response to chemotherapy. CC-486 and one of the CHOP drugs are taken orally (by mouth); the other three drugs are given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have peripheral T-cell lymphoma that has not yet been treated.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients ages 18-80.

For more information and to inquire about eligibility for this study, please contact Dr. Alison Moskowitz at 212-639-4839.